Merck Endometrial Cancer Studies Show Significant Survival Gains
Key takeaways
- Merck’s new and existing drugs deliver clear survival gains in endometrial cancer, potentially expanding its oncology portfolio.
- Sacituzumab tirumotecan reduced death risk by 32%
- Median overall survival 19.0 months vs 12.1 months
- Median progression‑free survival 7.2 months vs 3.9 months
What happened
Merck & Co. announced that its antibody‑drug conjugate sacituzumab tirumotecan and its immunotherapy Keytruda both showed significant survival benefits in late‑stage endometrial cancer trials presented at the European Society for Medical Oncology Congress 2026.
Why it matters
The TroFuse‑005 Phase 3 study is the first global trial of an antibody‑drug conjugate to beat chemotherapy in this patient group, while KEYNOTE‑C93 confirms Keytruda’s strong activity in mismatch‑repair‑deficient tumors. These results could broaden treatment options and improve outcomes for patients with advanced or…
Short-term and longer-term
Short-term. Merck shares fell 2.37% to $141.82 after the announcement, reflecting short‑term market caution.
Longer-term. Over the next few months, investors should monitor how these results influence Merck’s oncology pipeline valuation and potential partnership or licensing opportunities.
Words on this card
- Antibody‑drug conjugate (ADC)
- A targeted therapy that links an antibody to a chemotherapy drug to deliver the toxin directly to cancer cells.
- Mismatch repair deficient (dMMR)
- A genetic condition where cancer cells lack DNA repair mechanisms, making them more responsive to certain immunotherapies.
- Progression‑free survival (PFS)
- The length of time during and after treatment that a patient lives without the cancer getting worse.
- Overall survival (OS)
- The duration a patient remains alive after starting treatment.
- Objective response rate (ORR)
- The proportion of patients whose cancer shrinks or disappears after treatment.
- Biologics License Application (BLA)
- A regulatory submission to the FDA for approval of a biologic drug.